Edaravone for treatment of cerebral hemorrhage: Report of 30 cases

Objective: To observe the clinical effect of edaravone on intracerebral hemorrhage(ICH).Methods: Sixty patients with ICH were randomly assigned to two groups.Thirty patients in the treatment group were given edaravone in addition to the routine therapy for 14 days and the other 30 patients were treated routinely.The degree of neurologic impairment before treatment and at 14th and 28th day after treatment was compared between the two groups by the National Institute of Health Stroke Scale(NIHSS).The prothrombin time(PT),activated partial thromboplastin time(APTT) and fibrinogen(FG) were recorded before and after edaravone therapy in the treatment group.Results: The NIHSS of the treatment group was obviously lower than that of the control group(P<0.01).The PT,APTT and FG had no significant change in the treatment group(P>0.05).The treatment group had no more incidence of adverse drug reaction than the control group(P>0.05).Conclusions: Edaravone is an efficacious and safe therapeutic agent for ICH.